Lamisil At (Terbinafine Hydrochloride)

Terbinafine blocks the fungal enzyme squalene epoxidase, preventing the synthesis of ergosterol, an essential component of fungal cell membranes. This disruption leads to accumulation of toxic squalene and ultimately causes fungal cell death while sparing human cells.

The specific dose and frequency of Lamisil At are determined by the prescribing healthcare professional based on the infection type, severity, patient age, and other clinical factors. Patients should follow the prescriber’s instructions exactly.

Safety data for topical terbinafine during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Lamisil At.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with azole antifungals, terbinafine has a different mechanism—squalene epoxidase inhibition—offering rapid fungicidal activity. It is often preferred for dermatophyte infections due to its high efficacy and lower rates of resistance, though choice of therapy should be individualized by the clinician.

Lamisil At should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from excess moisture, direct sunlight, and heat sources to maintain stability and potency.

Apply a thin layer of the cream to the affected skin area once or twice daily, as directed by the prescriber. Gently rub it in until fully absorbed, and wash hands before and after application to avoid accidental contact with eyes or mucous membranes.

Although rare, serious adverse reactions can include severe allergic responses such as swelling, hives, difficulty breathing, or a widespread skin rash like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Lamisil At should be avoided in individuals with known hypersensitivity to terbinafine or any component of the formulation. It is also not recommended for children under two years of age unless specifically prescribed, and patients with extensive skin damage or severe eczema should consult a clinician before use.